Company Overview

Update
Founded:
August 1, 2011
Headquarters:
Stony Brook, NY
Funding:
$600k
Categories:
Biotechnology

Synthetic Vaccine Design

Description

Update

Codagenix Inc. utilizes our breakthrough platform technology termed SAVE to construct live-attenuated viral vaccines against multiple targets. All live-attenuated vaccines that are currently used in the clinic were developed using a trial-and-error based method developed in the 1880s, pre-dating the discovery of the DNA double helix. Codagenix presents a breakthrough approach to live-attenuated vaccine design- were no longer would a vaccine developer blindly passage their target virus to construct a vaccine. The SAVE platform relies on synthetic biology and the “re-designing” of a target virus’s entire genome to yield a vaccine strain (Coleman JR. Science 2008; Muller SM. Nature Biotechnology 2010). This customization process uses software-based algorithms to ‘re-code’ the genome of a target virus. This genomic ‘re-coding’ results in a virus that is antigenically 100% identical (i.e. looks exactly like the wild-type, virulent... See More

Funding Rounds (1) - $600k

Update
  • $600k

    Investors Unknown
    Jul 1, 2012 -Grant

Offices/Locations (1)

Update
  • Headquarters

    25-108 Health Sciences Dr

    Stony Brook, NY 11794

    USA